Measurable Residual Disease (MRD) Focus

The role of MRD in multiple myeloma

VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.

MRD as a clinical and regulatory endpoint for AML

VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

DETERMINATION: the addition of ASCT to lenalidomide, bortezomib, and dexamethasone provides a PFS advantage for patients with newly diagnosed multiple myeloma

For decades, autologous stem cell transplants (ASCTs) with high-dose chemotherapy has been the standard of care for patients with newly…

Approval of axi-cel in second-line for R/R LBCL & label update

Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…

Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…

Brexucabtagene autoleucel receives FDA approval for R/R B-ALL

On October 1, 2021, the US Food and Drug Administration (FDA) approved the use of brexucabtagene autoleucel, an autologous CD19-directed…

Key trial updates from IMW 2021

VJHemOnc is excited to bring you the latest updates from 18th International Myeloma Workshop (IMW) 2021, which brought together leading…

CAR-T therapy updates for the treatment of B-ALL

The introduction of chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) has significantly…

EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

NYC-Miami Myeloma MRD 2020 Virtual Meeting

VJHemOnc is proud to present the NYC-Miami Myeloma MRD 2020 Virtual Meeting, which took place on the 8th of October…

FDA clears first in vitro diagnostic MRD assay for CLL

The U.S. Food and Drug Administration (FDA) has approved the first and only assay – clonoSEQ®, to screen and assess…

HemOnc & COVID-19 Session

In this session, Amer Zeidan, John Mascarenhas, Jan Bewersdorf & Rory Shallis discuss and debate the special considerations for managing…

Influencing post-transplant AML outcomes based on MRD status

Recently published in the Journal of Clinical Oncology, work from the Hourigan Lab (National Heart, Lung, and Blood Institute, National…

iwAL 2019
E-learning

VJHemOnc is pleased to bring you e-learning webcasts from iwAL 2019. Catch up on key topics in acute leukemias now!

Myeloma2018 E-learning

Explore the latest updates from Myeloma2018 with new e-learning webcasts available now!

features: MRD